{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:27:38Z","timestamp":1775636858433,"version":"3.50.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The early diagnosis and management of lung adenocarcinoma co-existing with tuberculosis (LAC-TB) presents significant challenges in clinical settings. This is compounded by a paucity of robust clinical evidence elucidating the interactions between these two conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included 14 patients diagnosed with LAC-TB, with an equal distribution among those with pulmonary tuberculosis (TB) and those with peripheral lymph node TB. Controls included patients with simple TB and those with lung adenocarcinoma (LAC). Histopathologic examinations confirmed typical changes in each group. Immunohistochemistry analyzed immune markers, focusing on PD-L1, while genomic analysis identified differential mutant genes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pathological evaluations showed that LAC-TB and LAC groups expressed TTF-1 and Napsin A in their adenocarcinoma specimens. Notably, a higher proportion of patients in the LAC-TB group had a Ki-67 proliferation index of \u226510%. Subsequent Molecular analyses revealed significant differences in RALGAPA1 gene expression, with the LAC-TB group also exhibiting a greater median count of missense mutations, single nucleotide polymorphisms, and overall mutations, suggesting a higher malignancy level than the LAC group. Additionally, the LAC-TB group showed an increased tumor mutational burden, indicating a potentially better response to immunotherapy. Immunohistochemical assessments indicated that <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (MTB) infection correlated with reduced infiltration of T cells and CD4<jats:sup>+<\/jats:sup> T cells, alongside an upregulation of PD-L1 expression in LAC. Notably, PD-L1 was strongly expressed in the TB granuloma and surrounding areas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings suggest that MTB infection may increase the malignancy of LAC, with the pronounced expression of PD-L1 in granuloma regions constituting a pivotal mechanism underlying this relationship.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1537520","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:05:57Z","timestamp":1740132357000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Mycobacterium tuberculosis infection may increase the degrees of malignancy in lung adenocarcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Shanshan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14213","article-title":"Lung cancer risk following previous abnormal chest radiographs: A 27-year follow-up study of a chinese lung screening cohort","volume":"12","author":"Fan","year":"2021","journal-title":"Thorac Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13027-022-00434-2","article-title":"The relationship between previous pulmonary tuberculosis and risk of lung cancer in the future","volume":"17","author":"Qin","year":"2022","journal-title":"Infect Agents Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1361326","article-title":"Il-10 and tgf-beta1 may weaken the efficacy of preoperative anti-tuberculosis therapy in older patients with spinal tuberculosis","volume":"14","author":"Li","year":"2024","journal-title":"Front Cell infection Microbiol"},{"key":"B4","first-page":"17","article-title":"Tuberculosis and lung cancer","volume":"91","author":"Tamura","year":"2016","journal-title":"Kekkaku: [Tuberculosis]"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8050700","article-title":"Factors for the early revision of misdiagnosed tuberculosis to lung cancer: A multicenter study in a tuberculosis-prevalent area","volume":"8","author":"Shu","year":"2019","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20021282","article-title":"The bidirectional relationship between pulmonary tuberculosis and lung cancer","volume":"20","author":"Preda","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.21037\/atm-20-5964","article-title":"Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis","volume":"8","author":"Ye","year":"2020","journal-title":"Ann Trans Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159683","article-title":"Post-inhaled corticosteroid pulmonary tuberculosis increases lung cancer in patients with asthma","volume":"11","author":"Jian","year":"2016","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030765","article-title":"Pulmonary tuberculosis and risk of lung cancer: A systematic review and meta-analysis","volume":"11","author":"Hwang","year":"2022","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.32","article-title":"Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control","volume":"28","author":"Nalbandian","year":"2009","journal-title":"Oncogene"},{"key":"B11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s42003-020-01318-0","article-title":"Lung gene expression signatures suggest pathogenic links and molecular markers for pulmonary tuberculosis, adenocarcinoma and sarcoidosis","volume":"3","author":"Chai","year":"2020","journal-title":"Commun Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-22-272","article-title":"Clinical characteristics and survival of patients concurrently diagnosed with lung cancer and active pulmonary tuberculosis","volume":"11","author":"Lee","year":"2022","journal-title":"Trans Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-465","article-title":"Advances in molecular mechanisms of interaction between mycobacterium tuberculosis and lung cancer: A narrative review","volume":"10","author":"Xiong","year":"2021","journal-title":"Trans Lung Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.05.030","article-title":"Management of co-existent tuberculosis and lung cancer","volume":"122","author":"Ho","year":"2018","journal-title":"Lung Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18053\/jctres.07.202101.001","article-title":"Immunotherapy in non-small cell lung cancer: update and new insights","volume":"7","author":"Mielgo-Rubio","year":"2021","journal-title":"J Clin Trans Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e003956","DOI":"10.1136\/jitc-2021-003956","article-title":"Society for immunotherapy of cancer (Sitc) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma","volume":"10","author":"Govindan","year":"2022","journal-title":"J immunotherapy Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond pd-1 and ctla-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000488","article-title":"Overview of lung cancer immunotherapy","volume":"26","author":"Sanmamed","year":"2020","journal-title":"Cancer J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071681","article-title":"Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers","volume":"14","author":"Pena-Romero","year":"2022","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1186\/s12885-020-07622-6","article-title":"The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: A retrospective analysis","volume":"20","author":"Chai","year":"2020","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-524","article-title":"The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with mycobacterium tuberculosis infection","volume":"10","author":"Shi","year":"2021","journal-title":"Trans Lung Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":". CA: Cancer J Clin"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2868","article-title":"Pd-1 inhibitors for non-small cell lung cancer patients with special issues: real-world evidence","volume":"9","author":"Byeon","year":"2020","journal-title":"Cancer Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with hisat2 and hisat-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020192283","article-title":"Lung cancer ct screening and lung-rads in a tuberculosis-endemic country: the korean lung cancer screening project (K-lucas)","volume":"296","author":"Kim","year":"2020","journal-title":"Radiology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0873","article-title":"Lower risk of lung cancer after multiple pneumonia diagnoses","volume":"19","author":"Koshiol","year":"2010","journal-title":"Cancer epidemiology Biomarkers prevention: Publ Am Assoc Cancer Research cosponsored by Am Soc Prev Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30384","article-title":"Tuberculosis, smoking and risk for lung cancer incidence and mortality","volume":"139","author":"Hong","year":"2016","journal-title":"Int J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7150\/jca.37022","article-title":"Pulmonary tuberculosis is associated with elevated risk of lung cancer in korea: the nationwide cohort study","volume":"11","author":"Oh","year":"2020","journal-title":"J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1040163","article-title":"Chronic inflammation, cancer development and immunotherapy","volume":"13","author":"Wen","year":"2022","journal-title":"Front Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal transduction targeted Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0831","article-title":"Robot-assisted lobectomy for pulmonary tuberculosis in a case with immunosuppression after kidney transplantation","volume":"22","author":"Yablonskii","year":"2018","journal-title":"Int J tuberculosis Lung disease: Off J Int Union against Tuberculosis Lung Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad373","article-title":"Increased lung cancer risk and associated risk factors in tuberculosis survivors: A korean population-based study","volume":"77","author":"Moon","year":"2023","journal-title":"Clin Infect diseases: an Off Publ Infect Dis Soc America"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278661","article-title":"Tuberculosis and risk of cancer: A systematic review and meta-analysis","volume":"17","author":"Luczynski","year":"2022","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"13559","DOI":"10.1038\/s41598-021-92667-1","article-title":"Pge2 displays immunosuppressive effects during human active tuberculosis","volume":"11","author":"Pellegrini","year":"2021","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1086\/511277","article-title":"Immunosuppression during active tuberculosis is characterized by decreased interferon- gamma production and cd25 expression with elevated forkhead box P3, transforming growth factor- beta, and interleukin-4 mrna levels","volume":"195","author":"Roberts","year":"2007","journal-title":"J Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2022.151558","article-title":"Can mycobacterium tuberculosis infection lead to cancer? Call for a paradigm shift in understanding tb and cancer","volume":"312","author":"Malik","year":"2022","journal-title":"Int J Med microbiology: IJMM"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2020.01.002","article-title":"Bi-allelic variants in ralgapa1 cause profound neurodevelopmental disability, muscular hypotonia, infantile spasms, and feeding abnormalities","volume":"106","author":"Wagner","year":"2020","journal-title":"Am J Hum Genet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.03.020","article-title":"Rala signaling pathway as a therapeutic target in hepatocellular carcinoma (Hcc)","volume":"8","author":"Ezzeldin","year":"2014","journal-title":"Mol Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40248-015-0034-z","article-title":"DNA damage and cellular abnormalities in tuberculosis, lung cancer and chronic obstructive pulmonary disease","volume":"10","author":"da Silva","year":"2015","journal-title":"Multidiscip Respir Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116203","article-title":"Tumor immunotherapy resistance: revealing the mechanism of pd-1\/pd-L1-mediated tumor immune escape","volume":"171","author":"Cui","year":"2024","journal-title":"Biomedicine pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discovery"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to pd-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"New Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to ctla-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"New Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00752-4","article-title":"The association between tumor mutational burden and prognosis is dependent on treatment context","volume":"53","author":"Valero","year":"2021","journal-title":"Nat Genet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of pd-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann oncology: Off J Eur Soc Med Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.03.015","article-title":"Immune checkpoint inhibitor use and tuberculosis: A systematic review of the literature","volume":"132","author":"Zaemes","year":"2020","journal-title":"Eur J Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1186\/s12879-021-06845-7","article-title":"Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: A case report","volume":"21","author":"Lau","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1250LE","article-title":"Implications of tuberculosis reactivation after immune checkpoint inhibition","volume":"198","author":"Elkington","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (Oak): A phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031619","article-title":"Pd-L1 expression in monocytes correlates with bacterial burden and treatment outcomes in active pulmonary tuberculosis","volume":"23","author":"Pan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01121-x","article-title":"The immunoregulatory landscape of human tuberculosis granulomas","volume":"23","author":"McCaffrey","year":"2022","journal-title":"Nat Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24590","article-title":"Strong pd-L1 expression in granulomatous prostatitis","volume":"83","author":"Dikov","year":"2023","journal-title":"Prostate"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119333","article-title":"Exosomes: from garbage bins to translational medicine","volume":"583","author":"Liu","year":"2020","journal-title":"Int J pharmaceutics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.3390\/life12122104","article-title":"Potential role of tumor-derived exosomes in non-small-cell lung cancer in the era of immunotherapy","volume":"12","author":"Tartarone","year":"2022","journal-title":"Life"},{"key":"B56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13046-023-02753-7","article-title":"Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts","volume":"42","author":"Khan","year":"2023","journal-title":"J Exp Clin Cancer research: CR"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8839978","article-title":"Clinical implications of exosomal pd-L1 in cancer immunotherapy","volume":"2021","author":"Ayala-Mar","year":"2021","journal-title":"J Immunol Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/s41598-022-05749-z","article-title":"Clinical and pathological characteristics associated with the presence of the is6110 mycobacterim tuberculosis transposon in neoplastic cells from non-small cell lung cancer patients","volume":"12","author":"Arrieta","year":"2022","journal-title":"Sci Rep"},{"key":"B59","first-page":"7","article-title":"A comprehensive study on the correlation of treatment, diagnosis and epidemiology of tuberculosis and lung cancer","volume":"22","author":"Sheikhpour","year":"2023","journal-title":"Tanaffos"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1537520\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:06:01Z","timestamp":1740132361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1537520\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2025.1537520"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1537520","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"article-number":"1537520"}}